Literature DB >> 21491129

[Calciphylaxis. A call for interdisciplinary cooperation].

V M Brandenburg1, S Schmitz, J Floege, K Amann, M Ketteler.   

Abstract

Calciphylaxis is a rare, often very painful and potentially life-threatening disorder at the interface between nephrology and dermatology. It is characterized by skin lesions and ulcerations following calcification and occlusion of cutaneous arterioles. Most patients have chronic kidney disease or are on dialysis. A concert of various, still incompletely understood local and systemic risk factors is necessary to cause the development of calciphylaxis. Since randomized prospective trials are missing, interdisciplinary treatment is based on pathophysiological considerations as well as evidence derived from case reports or case series. Normalization of mineral metabolism, intensifying dialysis and avoidance of coumarins, as well as administration of calcimimetics, bisphosphonates and sodium thiosulfate and hyperbaric oxygen therapy are often used. Supportive measures include analgesics, antibiotics and local wound care. We have initiated an internet-based registry for patients with calciphylaxis in order to collect data for improved patient care (with support from Amgen) (www.calciphylaxie.de).

Entities:  

Mesh:

Year:  2011        PMID: 21491129     DOI: 10.1007/s00105-011-2169-y

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  27 in total

1.  Sensitization to calciphylaxis by endogenous parathyroid hormone.

Authors:  H SELYE; G GABBIANI; R STREBEL
Journal:  Endocrinology       Date:  1962-10       Impact factor: 4.736

2.  On the role of adjuvants in calciphylaxis.

Authors:  H SELYE; S GRASSO; J M DIEUDONNE
Journal:  Q Rev Allergy Appl Immunol       Date:  1961 Jul-Aug

3.  Calciphylaxis: natural history, risk factor analysis, and outcome.

Authors:  Roger H Weenig; Lindsay D Sewell; Mark D P Davis; James T McCarthy; Mark R Pittelkow
Journal:  J Am Acad Dermatol       Date:  2006-12-01       Impact factor: 11.527

Review 4.  Calcific uremic arteriolopathy: advances in pathogenesis and treatment.

Authors:  Natasha M Rogers; David J O Teubner; P Toby H Coates
Journal:  Semin Dial       Date:  2007 Mar-Apr       Impact factor: 3.455

5.  Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy.

Authors:  Adrian Fine; James Zacharias
Journal:  Kidney Int       Date:  2002-06       Impact factor: 10.612

6.  Calciphylaxis in patients on hemodialysis: a prevalence study.

Authors:  M Angelis; L L Wong; S A Myers; L M Wong
Journal:  Surgery       Date:  1997-12       Impact factor: 3.982

Review 7.  Calciphylaxis from nonuremic causes: a systematic review.

Authors:  Sagar U Nigwekar; Myles Wolf; Richard H Sterns; John K Hix
Journal:  Clin J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 8.237

Review 8.  Cutaneous necrosis from calcific uremic arteriolopathy.

Authors:  T Coates; G S Kirkland; R B Dymock; B F Murphy; J K Brealey; T H Mathew; A P Disney
Journal:  Am J Kidney Dis       Date:  1998-09       Impact factor: 8.860

9.  Sodium thiosulfate, bisphosphonates, and cinacalcet for treatment of calciphylaxis.

Authors:  Colette B Raymond; Lori D Wazny
Journal:  Am J Health Syst Pharm       Date:  2008-08-01       Impact factor: 2.637

Review 10.  Uremic small-artery disease with medial calcification and intimal hyperplasia (so-called calciphylaxis): a complication of chronic renal failure and benefit from parathyroidectomy.

Authors:  J Hafner; G Keusch; C Wahl; B Sauter; A Hürlimann; F von Weizsäcker; M Krayenbühl; K Biedermann; U Brunner; U Helfenstein
Journal:  J Am Acad Dermatol       Date:  1995-12       Impact factor: 11.527

View more
  2 in total

Review 1.  Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease-mineral and bone disorder.

Authors:  Vincent M Brandenburg; Smeeta Sinha; Paula Specht; Markus Ketteler
Journal:  Pediatr Nephrol       Date:  2014-01-29       Impact factor: 3.714

2.  Ecto-5' -Nucleotidase CD73 (NT5E), vitamin D receptor and FGF23 gene polymorphisms may play a role in the development of calcific uremic arteriolopathy in dialysis patients - Data from the German Calciphylaxis Registry.

Authors:  Hansjörg Rothe; Vincent Brandenburg; Margot Haun; Barbara Kollerits; Florian Kronenberg; Markus Ketteler; Christoph Wanner
Journal:  PLoS One       Date:  2017-02-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.